Cheng Lung Ku is Director of the Center for Molecular and Clinical Immunology, where his research focuses on the mechanisms of human immune dysregulation that underlie susceptibility to infection and autoimmunity. He pioneered the study of anti-cytokine autoantibodies, identifying anti–interferon-γ autoantibodies as a major cause of disseminated nontuberculous mycobacterial disease, defining their HLA associations, and demonstrating their broader impact on host defense against diverse pathogens. His laboratory subsequently established high-throughput platforms for human monoclonal antibody cloning, enabling systematic dissection of pathogenic anti-cytokine autoantibodies across multiple specificities. His work has been published in Nature Medicine, Blood, The Journal of Experimental Medicine, and Science Immunology. Ku has received multiple honours, including the Outstanding Research Scholar Award from the Chinese Society of Immunology (Taiwan), the Academia Sinica Young Scholar Publication Award, and the Wu Ho-Su Medical Award. Beyond fundamental immunology, his group advances translational research in autoimmune nephropathies, vitiligo, and immune-cell–based therapies, with a strong emphasis on drug development. This bench-to-bedside vision has been recognised by major technology transfer awards, reflecting his leadership at the interface of discovery science and clinical innovation.